Peptonic Medical AB (publ) issues its Annual Report 2017
Stockholm, March 7th 2018. - Peptonic Medical (publ) - today announces that its 2017 Annual Report is available on the Company’s website www.peptonicmedical.se and on the website of Aktietorget www.aktietorget.se.
In the Auditor’s Report the following information is presented under the heading ‘Additional Information’ (sv. Övriga upplysningar): “We refer to the Annual Report that states that a need for additional financing may occur during the coming 12 months and that there is always the possibility to turn to the shareholders, however, there is no absolute guarantee that a rights issue will be successful.”
For more information on Peptonic Medical AB (publ), please contact:
Johan Inborr, CEO
Telephone +46 708 853 893
VagiVital® is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
PEPTONIC Medical plans to launch VagiVital® as a non-prescription self-care product in 2018.
Peptonic Medical AB (publ) is an innovative Swedish biopharma company developing medicinal products within the field of Women’s Health. Our vision is to offer safe and effective treatments to women suffering from women specific diseases and conditions. The Company’s first product - VagiVital® - has been developed for the treatment of Vaginal Atrophy (VA), a disease affecting approximately fifty per cent of women in menopause and after. VagiVital® is a trademark of Peptonic Medical.
The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
In July 2014, Peptonic Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.
For more information: www.peptonicmedical.com